Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial

Journal:

Nature Communications

Published:

2026-04-04

DOI:

10.1038/s41467-026-71155-y

Affiliations:

19

Authors:

24

Go to article

Institutions	Authors	Share
Vall d'Hebron University Hospital (HUVH), ICS, Spain	5.000000	0.21
Hospital Universitario Ramón y Cajal, Spain	2.000000	0.08
Bellvitge Biomedical Research Institute (IDIBELL), Spain	2.000000	0.08
La Paz University Hospital, UAM, Spain	2.000000	0.08
Hospital Universitario 12 de Octubre, Spain	2.000000	0.08
Instituto Valenciano de Oncologia (IVO), Spain	2.000000	0.08
Hospital General Universitario Morales Meseguer, Spain	1.000000	0.04
University of Murcia (UMU), Spain	1.000000	0.04
Institute of Biomedical Research in Malaga (IBIMA), Spain	1.000000	0.04
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain	1.000000	0.04
Complejo Hospitalario Universitario de Vigo (CHUVI), Spain	1.000000	0.04
Consorci Hospitalari Provincial de Castellón, Spain	1.000000	0.04
Health Research Institute of San Carlos (IdISSC), Spain	1.000000	0.04
MD Anderson Cancer Center Madrid, Spain	1.000000	0.04
Clara Campal Comprehensive Cancer Center HM CIOCC, Spain	0.500000	0.02
Princess Margaret Cancer Centre, U of T, Canada	0.500000	0.02

Interested in Oncology and Carcinogenesis?